Search
Reden_BPK_2016.pdf
Boehringer_Ingelheim_Annual_Report_2015.pdf
Boehringer_Ingelheim_company_profile_2015.pdf
add-on_therapy_Moroni-Zentgraf.pdf
Efficacy_Moroni-Zentgraf.pdf
Safety_Moroni-Zentgraf.pdf
supplier_code_of_conduct_010616_TR.pdf
Boehringer_Ingelheim_Corporate_Factsheet.pdf
Reden_BPK_2017.pdf
Boehringer_Ingelheim_Kurzbericht_2016.pdf
Speeches_APC_2017.pdf
Boehringer_Ingelheim_Summary_Report_2016.pdf
Boehringer_Ingelheim_Annual_Report_2016.pdf
Boehringer_Ingelheim_Unternehmensbericht_2016.pdf
Boehringer_Ingelheim_Company_Profile_2017.pdf
Praesentation_BPK_2017.pdf
Boehringer_Ingelheim_Consolidated_Companies_2016.pdf
Presentations_APC_2017.pdf
FSA-Transparenzbericht Boehringer Ingelheim 2016.pdf
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
EMA filing acceptance and validation for spesolimab
The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
environmental sustainability commitments
On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
commitments to sustainable development
On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
emperor-preserved-kidney-subanalysis
New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status